TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naive CD30-positive mature T-cell and NK-cell neoplasms, including systemic anaplastic large cell lymphoma~* Measurable disease of at least 1.5 cm~* ECOG performance status less than or equal to 2~Exclusion Criteria:~* Known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy~* Current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, Sezary syndrome or other primary cutaneous lymphomas; extranodal NK/T-cell lymphoma, nasal type~* History of another primary malignancy that has not been in remission for at least 3 years~* Left ventricular ejection fraction \<45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months~* Viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin~* Known human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus positive status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Sequential
- 2 (Type: EXPERIMENTAL): Combination
- 3 Brentuximab vedotin/CH-P (Type: EXPERIMENTAL): Combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 and above.~* COVID-19 infection and symptom onset no more than 5 days, with or without prior vaccination.~* WHO CPS 1-4~* Indicated for nirmatrelvir-ritonavir treatment~Exclusion Criteria:~* Patients cannot swallow capsules or adhere to protocol.~* Severe COVID-19 disease, including patients who require oxygen supplement therapy~* Significant hypersensitivity to nirmatrelvir, ritonavir, or any component of the formulation~* Patients require co-administration of drugs that are highly dependent on CYP3A4 for clearance and cannot be omitted during the treatment period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study : LEVOBUPIVACAINE Versus Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \> 18 years~* all patients requiring a non-urgent caesarian done according to the Misgav-Ladach technique~Exclusion Criteria:~* Patients requiring very urgent caesarian~* allergic to levobupivacaïne~* with previous history of alcoholism or drug addiction~* with severe hypotension or an ischemic cardiopathy badly compensated or thyrotoxicoses~* treated with first generation of IMAO (monoamine oxidase inhibitor) or with anti-arrhytmia drugs with anesthesic activity

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): patient who received levobupivacaïne
- 2 (Type: PLACEBO_COMPARATOR): patient who received placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV melanoma~  * Mucosal or ocular melanoma allowed~* Clinically evaluable disease~* HLA-A\*0201 positive~PATIENT CHARACTERISTICS:~Age:~* 16 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 6 months~Hematopoietic:~* WBC at least 2,500/mm\^3~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~* Hematocrit at least 30%~Hepatic:~* AST no greater than 3 times upper limit of normal (ULN)~* Bilirubin no greater than ULN (less than 3.0 mg/dL in patients with Gilbert's syndrome)~* Hepatitis B surface antigen negative~* Hepatitis C antibody nonreactive~Renal:~* Creatinine less than 2.0 mg/dL~Immunologic:~* Antinuclear antibody negative~* Thyroglobulin antibody normal~* Rheumatoid factor normal~* HIV negative~* No prior autoimmune disease (including uveitis and autoimmune inflammatory eye disease)~* No active infection~* No hypersensitivity to Montanide ISA-51~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix~* No other underlying medical condition that would preclude study therapy~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 3 weeks since prior immunotherapy for melanoma and recovered~* No prior gp100 peptides~* No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody~Chemotherapy:~* At least 3 weeks since prior chemotherapy for melanoma and recovered~* No concurrent chemotherapy~Endocrine therapy:~* At least 3 weeks since prior hormonal therapy for melanoma and recovered~* At least 4 weeks since prior systemic or topical corticosteroids~* No concurrent topical or systemic corticosteroids~Radiotherapy:~* At least 3 weeks since prior radiotherapy for melanoma and recovered~Surgery:~* Not specified~Other:~* No other concurrent immunosuppressive agents (e.g., cyclosporine and its analog)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 6-12~* Previously healthy~* Attending physician concludes that the patient would benefit from administration of an anxiolysis medication prior to a minor procedure~Exclusion Criteria:~* Moderate to severe asthma or other chronic lung disease~* Co-morbid conditions including cerebral palsy, developmental delay, or other chronic illness deemed by the Attending physician to be unsafe to receive anxiolysis with Versed.~* Any child presenting with a life-threatening condition.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Intranasal Lidocaine (Type: EXPERIMENTAL): Patient to receive 4% lidocaine intranasally prior to midazolam
- Intranasal 0.9% saline (Type: PLACEBO_COMPARATOR): Patient to receive 0.9% Saline intranasally prior to midazolam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subconjunctival Bevacizumab and Recurrent Pterygium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent pterygium~Exclusion Criteria:~* Pregnant or lactating women~* History of myocardial infarction~* History of stroke

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Subconjunctival Bevacizumab (Type: EXPERIMENTAL): One aplication of subconjunctival Bevacizumab 0,5 ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation of AcrySof® IQ PanOptix™ IOL Model TFNT00

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision~* Able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures~* Clear intraocular media other than cataract in both eyes.~* Preoperative keratometric astigmatism of less than 1.0 diopter (D) in both operative eyes.~Exclusion Criteria:~* Clinically significant corneal abnormalities including corneal dystrophy, irregularity, inflammation or edema~* Previous refractive surgery or refractive surgery procedures (including, but not limited to LASIK, astigmatic keratotomy, and limbal relaxing incisions)~* Glaucoma (uncontrolled or controlled with medication)~* Degenerative eye disorders (e.g. macular degeneration or other retinal disorders)~* Pregnant or lactating~* Expected to require a second surgical intervention or retinal laser treatment.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multifocal IOL (Type: EXPERIMENTAL): AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
- Monofocal IOL (Type: ACTIVE_COMPARATOR): AcrySof Monofocal IOL Model SN60AT implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Codeine Plus Paracetamol Versus Placebo for PRK Post-operative Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* older than 20 years~* spherical component between -1.00 and -5.00, with or without astigmatism~* cylindrical component up to 1.5D~* spherical anisometropia of less than or equal to 0.75D,~* cylindrical anisometropia of less than or equal to 0.5D,~* stable refraction errors (maximal variation of 0.5D in the spherical or cylindrical component during 1 year)~* amenable to follow-up for at least seven (7) days.~Exclusion Criteria:~* presence of active disease of allergic, inflammatory or infectious nature, in the ocular surface or its attachments~* previous ocular history (pathology, surgery or ocular trauma)~* best corrected visual acuity less than 20/25)~* autoimmune disease, or immunosuppression or Diabetes Mellitus~* pregnancy or lactation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Codeine plus paracetamol (Type: ACTIVE_COMPARATOR): Codeine plus paracetamol every 6 hours for 72 hours after photorefractive keratectomy.
- placebo (Type: PLACEBO_COMPARATOR): Placebo every 6 hours for 72 hours after photorefractive keratectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of type 2 diabetes mellitus prior to informed consent~* Male and female patients on diet and exercise regimen who are:~  1. drug-naïve, defined as no antidiabetic drugs for 10 weeks prior to informed consent.~ 2. pre-treated with one oral antidiabetic drug; the present antidiabetic therapy has to be unchanged for 10 weeks prior to informed consent.~* HbA1c at Visit 1a:~  1. for patients who are drug naïve: HbA1c \>=7.0 to =\<10.0%~ 2. for patients treated with one oral antidiabetic drug: HbA1c \>=6.5 to =\<9.0%~* HbA1c of \>=7.0% and =\<10% at Visit 2 (start of run-in)~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose level \>240 mg/dL (\>13.3 mmol/L) after an overnight fast during wash-out/placebo run-in period and confirmed by a second measurement (not on the same day).~* Acute coronary syndromes, stroke or transient ischaemic attack within 12 weeks prior to informed consent~* Impaired renal function, defined as calculated eGFR \<60 ml/min (MDRD formula) during screening and/or wash-out period and/or run-in phase.~* Bariatric surgery within the past 2 years and other gastrointestinal surgeries that induce chronic malabsorption~* Blood dyscrasias or any disorders causing hemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia)~* Treatment with anti-obesity drugs (e.g. sibutramine, mazindol) 12 weeks prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose QD (Type: EXPERIMENTAL): BI 10773 tablets low dose once a day
- BI 10773 mid-low dose QD (Type: EXPERIMENTAL): BI 10773 tablets mid-low dose once a day
- BI 10773 mid-high dose QD (Type: EXPERIMENTAL): BI 10773 tablets mid-high dose once a day
- BI 10773 high dose QD (Type: EXPERIMENTAL): BI 10773 tablets high dose once a day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed locally confined adenocarcinoma of the prostate with primary tumors confined to the prostate, clinical stage T1b,1c, 2a or 2b.~* Negative nodes evaluated by imaging methods (classified in the study as NX) or by surgical sampling (classified in the study as N0).~* Karnofsky performance status ≥ 70.~* PSA is mandatory, must be ≤ 20)~* No prior hormonal therapy, radiation or chemotherapy.~* Prior finasteride for prostate hypertrophy allowed if discontinued at least 60 days prior to randomization.~* Prior testosterone administration allowed if at least 90 days elapsed since last administration.~* No evidence of distant metastasis or other synchronous primary. Patients with prior invasive malignancy who were disease free for at least 5 years could be eligible with pre-randomization approval by the study chairman.~* Treatment begins within 21 days after randomization.~* Patients signs a study-specific informed consent form.~* Alanine Aminotransferase (ALT) within 2x upper normal limits.~Exclusion criteria:~* Stage T1a or ≥ T2c disease.~* Lymph node involvement (N1 - N3).~* Evidence of distant metastasis. (M1)~* PSA \> 20.~* Radical surgery or cryosurgery for carcinoma of the prostate, previous irradiation, antiandrogen therapy or chemotherapy.~* Previous or concurrent cancers other than basal cell or squamous cell skin carcinoma.~Patients with squamous cell carcinomas required to be NED (no evidence of disease) for a minimum of two years prior to study entry.~* Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.~* Karnofsky performance status of \< 70.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant TAS + RT (Type: EXPERIMENTAL): Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.
- Radiation therapy alone (Type: OTHER): Radiation therapy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve~* Age older than 18 years old~* Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive \> 6 months~* Detectable serum quantitative HCV-RNA (Cobas Taqman HCV Monitor v2.0, Roche Diagnostics) with dynamic range 25 \~ 391000000 IU/ml~* HCV genotype 2 (Inno-LiPA HCV II, Innogenetics, Ghent, Belgium)~* Serum alanine aminotransferase levels above the upper limit of normal with 6 months of enrollment~* A liver biopsy consistent with the diagnosis of chronic hepatitis C~Exclusion Criteria:~* Anemia (hemoglobin \< 13 grams per deciliter for men and \< 12 grams per deciliter for women)~* Neutropenia (neutrophil count \< 1,500 per cubic milliliter)~* Thrombocytopenia (platelets \< 90,000 per cubic milliliter)~* Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Chronic alcohol abuse (daily consumption \> 20 grams per day)~* Decompensated liver disease (Child-Pugh class B or C)~* Serum creatinine level more than 1.5 times the upper limit of normal~* Autoimmune liver disease~* Neoplastic disease~* An organ transplant~* Immunosuppressive therapy~* Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases, psychiatric diseases, neurological diseases, diabetes mellitus~* Evidence of drug abuse~* Unwilling to use contraception~* Unwilling to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peg-IFN + WB RBV for 16 weeks (Type: ACTIVE_COMPARATOR): Weight-based ribavirin (1000-1200 mg/day) from weeks 1-16 in patients with RVR
- Peg-IFN + LD RBV for 16 weeks (Type: ACTIVE_COMPARATOR): Weight-based ribavirin (1000-1200 mg/day) from weeks 1-6, and then low dose ribavirin (800 mg/day) from weeks 6-16 in patients with RVR
- Peg-IFN + WB RBV for 24 weeks (Type: ACTIVE_COMPARATOR): Weight-based ribavirin (1000-1200 mg/day) from weeks 1-24 in patients without RVR
- Peg-IFN + WB RBV for 48 weeks (Type: ACTIVE_COMPARATOR): Weight-based ribavirin (1000-1200 mg/day) from weeks 1-48 in patients without RVR
- Peg-IFN + LD RBV for 24 weeks (Type: ACTIVE_COMPARATOR): Low dose ribavirin (800 mg/day) from weeks 1-24 in patients with or without RVR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extending Long-term Outcomes Through an Adaptive Aftercare Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* be age 18 years or older~* have a cocaine use disorder diagnosis~* be willing to sign informed consent and able to pass an informed consent quiz~Exclusion Criteria:~* serious, uncontrolled psychiatric illness~* in recovery from pathological gambling~* do not speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard care (Type: ACTIVE_COMPARATOR): standard care
- standard care plus traditional contingency managment (Type: ACTIVE_COMPARATOR): prize contingency management on a traditional twice weekly schedule for cocaine abstinence
- standard care plus variable interval contingency management (Type: EXPERIMENTAL): prize contingency management on a variable interval schedule for cocaine abstinence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete